Board of Directors
The EUSA Pharma Board of Directors is highly experienced in investment and pharmaceutical management, and provides strategic support as well as an extensive industry network.
Bryan Morton CBE
Bryan Morton founded EUSA Pharma, Inc in 2006. A transatlantic specialty pharmaceutical company focused on oncology and critical care. Bryan was the President and CEO of EUSA until the sale of the company to Jazz Pharmaceuticals for a total consideration of $700m in 2012. In March 2015 Bryan, together with Essex Woodlands reacquired certain EUSA assets from Jazz Pharmaceuticals in order to create a new specialty Pharma company, trading once again as EUSA Pharma. Prior to founding the original EUSA Pharma Bryan was the CEO of Zeneus Pharma, which he founded following the $120m acquisition of Elan’s European business. Zeneus was subsequently acquired by Cephalon in late 2005 for $360m after two highly successful years of rapid growth and profitable trading.
Bryan’s entrepreneurial success is built on 30 years of commercial business development and general management experience in the pharmaceutical industry, spent largely with Merck & Co Inc. and Bristol Myers Squibb. He has extensive international experience, particularly in the US and Europe, having held senior positions, including at Board and SVP level, in America, the UK, Belgium and Australia. Bryan is Executive Chairman of EUSA Pharma, Chairman of VHsquared and he is the Executive Chairman of Akaza Bioscience.
Bryan holds an MBA from Durham University and is an Honorary Professor at Durham University Business School. Bryan also holds a BSc in Pharmacology from Aberdeen University in Scotland and is a graduate of the INSEAD European Management Programme.
In 2016 Bryan was honored by Her Majesty the Queen and was awarded a CBE (Commander of the Most Excellent Order of the British Empire) for services to the Healthcare Industry.
Petri Vainio, MD, PhD, has spent his entire career as an investor and board member in rapidly growing healthcare companies. He has been a lead investor in numerous successful healthcare companies in all sectors, including pharmaceuticals, biotechnology, medical devices and healthcare services. Petri has served on the board of directors of over 20 private and public healthcare companies and has helped these companies raise over $1 billion in private financings and create a combined enterprise value of over $30 billion. Petri holds a Doctor of Medicine and a Doctor of Philosophy degree in Biochemistry from the University of Helsinki, as well as a Masters in Business Administration degree from Stanford University.
Dr Göran Ando is Senior Advisor with EUSA Pharma’s lead shareholder, EW Healthcare Partners. Dr Ando has over 35 years’ experience in the pharmaceutical industry, spent in a variety of senior international roles. He is the retired Chairman of Novo Nordisk, the world’s leading pharmaceutical company focused on diabetes. Previously, he was CEO of Celltech Group plc prior to its acquisition by UCB Pharma, and was Head of R&D at Pharmacia / Pharmacia & Upjohn. Dr Ando holds a Bachelor of Arts degree from Uppsala University in Sweden and a Medical Degree from Linkoeping University (Sweden).
Bill brings to EUSA 50 years' experience of the life sciences industry. In his most recent role, he was a General Partner at Healthcare Ventures, one of the world’s largest venture capital firms specialising in biotechnology. In addition to his 20 years venture capital experience, he was Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International. He currently serves on the Board of The Medicines Company (NASDAQ: MDCO), and is a Director of three private biotechnology companies. He is also a Trustee and Executive Committee Member of the New York Blood Center and is a member of Lehigh University’s Business Advisory Board. He holds a BS in Finance and Economics from Lehigh University and an MBA from Pace University.
Evis has over 10 years of experience in the healthcare industry. Previously, Evis was a senior manager in the European life sciences and healthcare team at LEK Consulting, a management consulting company. In this function, she was involved in several large business transactions in the healthcare space and in the evaluation of research and marketing initiatives and business plans for pharmaceutical and biotech companies. Evis received her Doctor of Philosophy degree from the University of Pennsylvania. Evis joined Essex Woodlands as Vice President, based in the London office, in September 2011 and was promoted to Principal in January 2013, followed by Partner in July 2017.
Rolf Hoffmann is one of the most respected operations executives in Big Pharma and recently in Biotech, having achieved remarkable results in significant countries around the world over the past 25 years.
Rolf headed Eli Lilly operations in Germany, Subsahara and South Africa as well as Latin America, before moving to Amgen to take on their International operations in Europe and subsequently the United States operations out of the U.S. Headquarters.
Since retiring from Amgen in July 2016, he has served on the Board of Danish Genmab (Europe's largest Biotech company), Trigemina Inc. (a U.S. biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies) and STADA (Germany's largest independent Generics/OTC enterprise), and as Chairman of Biotest AG (a German-based global provider of plasma proteins and biological drugs). He also consults with US- and European Biotech companies and WADA (World Anti- Doping Association). Furthermore, he is a member and VP External Affairs for the German-American Heritage Foundation.
Chief Financial Officer
Emma has more than 10 years' experience in healthcare companies. She completed the ACCA qualification as a chartered accountant and has acted in both financial and commercial director positions, including the senior management team of EUSA Pharma prior to its acquisition by Jazz Pharmaceuticals.
Chief Executive Officer
Carsten is a highly experienced commercial professional having spent more than 25 years in the pharmaceutical industry building on his knowledge of oncology and rare disease. He has held a variety of international leadership roles including CEO of Abeona Therapeutics Inc, CCO at Alexion and Head of Europe at Amgen. He also holds a PhD in Molecular Biology & Biochemistry.